Massachusetts 2023-2024 Regular Session

Massachusetts House Bill H1215

Introduced
2/16/23  

Caption

Relative to pharmacy benefit managers

Impact

If enacted, HB 1215 would have significant implications for state laws by reinforcing existing regulations regarding PBMs and introducing new requirements that could affect how they operate. This would include stipulations on how PBMs charge pharmacies for prescriptions, ensuring that payment practices are fair, and curbing predatory pricing and payment tactics that have led to increased out-of-pocket costs for consumers. The ultimate aim is to reduce the complexity and increase fairness in the pharmaceutical supply chain, thus ensuring that residents in Massachusetts have access to affordable medications without undue financial burden.

Summary

House Bill 1215 seeks to regulate pharmacy benefit managers (PBMs) in the Commonwealth of Massachusetts by establishing accountability and transparency within their operations. The bill addresses various aspects of PBMs including how they handle prescription drug pricing, reimbursement rates for pharmacies, and the general conduct of PBMs in their interactions with patients and healthcare providers. It emphasizes the provision of proper translation and interpretation of higher healthcare costs due to peripheral expenses inflicted by PBMs. By doing so, the bill aims to enhance access to necessary medications for residents while managing what has generally been perceived as excessive costs related to pharmaceutical benefits.

Contention

Notably, the bill has garnered both support and criticism. Proponents argue that it will lead to lower drug prices and increased transparency, thus fostering a more competitive environment that benefits consumers. Critics, however, have raised concerns that such regulations could inadvertently lead to fewer options for PBM services, potentially resulting in service reductions or increased costs in other areas of healthcare. They argue it may hinder PBMs' ability to negotiate effectively with pharmaceutical companies, thereby limiting patient access to new drugs or reducing rebates that could affect premiums of insurance plans reliant on PBM services.

Companion Bills

MA H4136

Similar To Relative to the Department of Unemployment Assistance Advisory Council

MA H4625

Similar To Relative to persons with developmental disabilities

MA H4658

Similar To Relative to Massachusetts Credit Union Share Insurance Corporation

MA H4709

Similar To Relative to adoptions

MA H4930

Similar To Relative to medical health and fitness facilities

MA S2492

Replaced by Relative to pharmaceutical access, costs and transparency

Previously Filed As

MA H1234

Relative to pharmacy benefit managers

MA S2492

Relative to pharmaceutical access, costs and transparency

MA S601

Prohibiting self-dealing by pharmacy benefit managers and pharmacies under common ownership

MA S749

Relative to pharmaceutical access, costs and transparency

MA S3012

Relative to pharmaceutical access, costs and transparency

MA H1176

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA S732

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA H1247

Relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth

MA H1330

Relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth

MA HB374

Health Insurance – Pharmacy Benefits Managers – Audits of Pharmacies and Pharmacists

Similar Bills

MA S2492

Relative to pharmaceutical access, costs and transparency

MA S749

Relative to pharmaceutical access, costs and transparency

NC H163

Pharmacy Benefits Manager Provisions

MA H945

To ensure prescription drug cost transparency and affordability

MA H1234

Relative to pharmacy benefit managers

MS HB1265

Pharmacists; authorize reimbursement for under certain insurance policies, plans, or contracts.

KY HB457

AN ACT relating to pharmacy or pharmacist services.

MS HB1298

Pharmacy benefit managers; require to use national average drug acquisition cost.